Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=68 Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
NSCLC Non-small Cell Lung Cancer
Primary: Event-free Survival (EFS) Rate — 73.4 percentage of participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=50 Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
Cancer
Primary: Evaluation of Overall Survival — 50.4 weeks
Phase 2 N=166 Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Phase 2 N=39 Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Phase 2 N=288 Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer · Efficacy
Primary: Progression Free Survival (PFS) — 168; 140 day
Phase 2 N=153 A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Phase 2 N=35 AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
NSCLC Stage IV
Primary: Objective Response Rate (ORR) — 6 Participants
Phase 3 N=219 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.7; 4.2 months
Phase 2 N=69 Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Clinical Response Rate — 17 Percentage of participants
Phase 1 N=8 Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
Non-squamous Non-small-cell Lung Cancer · Anlotinib
Primary: the Maximum Tolerated Dose (MTD) — 10 mg
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Phase 2 N=64 Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate (DCR) After 12 Weeks Induction — 0.742 proportion of participants
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Phase 3 N=357 Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
Phase 2 N=66 A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
Primary: Overall Response Rate (ORR) — 0; 3; 19; 2 Participants
Phase 2 N=25 Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
Lung Cancer
Primary: To Establish Rate of Non-progressive Disease at 4 Months in Patients With Advanced NSCLC Who Have Been Designated PS2 by Their Treating Physician — 28 percentage of…
Phase 2 N=32 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Phase 2 N=9 Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
Lung Cancer
Primary: Objective Response Rate (ORR), Presented in Numbers of Participants — 0; 0; 1; 1 Participants
Phase 3 N=583 Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
Primary: Overall Survival (OS) Time — 16.1; 15.5 months
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=33 Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents
Non-small Cell Lung Cancer
Primary: The Percentage of Patients That Respond to Treatment — 46; 29 percentage of patients
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 2 N=82 Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants
Phase 3 N=939 Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.89; 2.76; 2.37; 1.54 months — p=0.756
Phase 2 N=69 Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
Non-Small-Cell Lung Cancer
Primary: Median Time to Progression (TTP) — 6.11 months
Phase 2 N=20 Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung · Non-Small Cell Lung Cancer · Nonsmall Cell Lung Cancer
Primary: Response Rate (RR) — 3 Participants
Phase 2 N=13 Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases
Non-small Cell Lung Cancer
Primary: Intracranial Objective Response Rate — 6; 0; 5; 0 Participants